Skip to main content
SpringerLink
Log in

Clinical pharmacokinetics of nitrates

  • Nitrates
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied. For several reasons, including attenuation of the effects with time and the appearance of active metabolites, the relationship between the plasma concentrations of nitrates and their therapeutic effects is very complex. Knowledge of the pharmacokinetics of these substances is only of limited interest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bogaert MG, Rosseel MT. Plasma levels in man of nitroglycerin after buccal administration.J Pharm Pharmacol 1972;24:737–738.

    Google Scholar 

  2. Rosseel MT, Bogaert MG. GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.J Pharmaceut Sci 1973;62:754–758.

    Google Scholar 

  3. Bogaert MG. Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations.Clin Pharmacokin 1987;12:1–11.

    Google Scholar 

  4. Taylor T, Taylor IW, Chasseaud LF, et al. Pharmacokinetics and metabolism of organic nitrate vasodilators.Prog Drug Metab 1987;10:207–336.

    Google Scholar 

  5. Thadani U, Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.Clin Pharmacokin 1988;15:32–43.

    Google Scholar 

  6. Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.Int J Clin Pharmacol Ther Toxicol 1989;27:445–453.

    Google Scholar 

  7. Ahlner J, Andersson RGG, Torfgård K, et al. Organic nitrate esters: Clinical use and mechanisms of actions.Pharmacol Rev 1991;43:351–423.

    Google Scholar 

  8. Jaeger H, Lutz D, Michaelis K, et al. Determination of nitrates in plasma.Drugs 1987;33(Suppl 4):9–22.

    Google Scholar 

  9. Han C, Gumbleton M, Lau DTW, et al. Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites.J Chromatogr Biomed Appl 1992;579:237–235.

    Google Scholar 

  10. Jørgensen M, Andersen MP. Simultaneous determination of nitroglycerin and its dinitrate metabolites by capillary gas chromatography with electron-capture detection.J Chromatogr Biomed Appl 1992;577:167–170.

    Google Scholar 

  11. De Rudder D, Remon JP, Neyt EN. The absorption of nitroglycerin by infusion sets.J Pharm Pharmacol 1987;39:556–558.

    Google Scholar 

  12. Hansen HC, Spillum A. Loss of nitroglycerin during passage through two different infusion sets.Acta Pharm Nord 1991;3:131–136.

    Google Scholar 

  13. Haas CE, Nowak DR, Mabb WA. Effect of using a standard polyvinyl chloride intravenous infusion set on patient response to nitroglycerin.Am J Hosp Pharm 1992;49:1135–1137.

    Google Scholar 

  14. Fung H-L. Pharmacokinetics and pharmacodynamics of organic nitrates.Am J Cardiol 1987;60:4H-9H.

    Google Scholar 

  15. Fung H-L, Blei A, Chong S. Interpretation of nitrate plasma concentrations. Effect of cardiac output on nitroglycerin pharmacokinetics in experimental animals.Eur Heart J 1988;9(Suppl A):39–43.

    Google Scholar 

  16. Noonan PK, Benet LZ. The bioavailability of oral nitroglycerin.J Pharmaceut Sci 1986;75:241–243.

    Google Scholar 

  17. Yu DK, Williams RL, Benet LZ, et al. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing.Biopharm Drug Disp 1988;9:557–565.

    Google Scholar 

  18. Nakashima E, Rigod JF, Lin ET, et al. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses.Clin Pharmacol Ther 1990;47:592–598.

    Google Scholar 

  19. Kwon H-R, Green P, Curry SH. Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets.Biopharm Drug Disp 1992;13:141–152.

    Google Scholar 

  20. Mettle JKL, Glew RC, Jones MC, et al. Glyceryl trinitrate absorption: Chewing versus sublingual administration.Br J Clin Pract 1986;40:376–380.

    Google Scholar 

  21. Noonan PK, Benet LZ. Incomplete and delayed bioavailability of sublingual nitroglycerin.Am J Cardiol 1985;55:184–187.

    Google Scholar 

  22. Sanders SW, Michaelis K, Maurette JM, et al. Relative bioavailability of two spray formulations of nitroglycerin.J Pharmaceut Sci 1986;75:244–246.

    Google Scholar 

  23. Huber T, Merz P-G, Harder S, et al. Bioequivalence of sublingual glyceryl trinitrate.Arzneim Forsch/Drug Res 1990;40:1319–1322.

    Google Scholar 

  24. Wolff H-M, Bonn R. Principles of transdermal nitroglycerin administration.Eur Heart J 1989;10(Suppl A)26–29.

    Google Scholar 

  25. Nakashima E, Noonan PK, Benet LZ. Transdermal bioavailability and first-pass skin metabolism: A preliminary evaluation with nitroglycerin.J Pharmacokinet Biopharm 1987;15:423–437.

    Google Scholar 

  26. Jordan RA, Seth L, Casebolt P, et al. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure.Ann Intern Med 1986;104:295–298.

    Google Scholar 

  27. McAllister A, Mosberg H, Settlage JA, et al. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid.Br J Clin Pharmacol 1986;21:365–369.

    Google Scholar 

  28. Noonan PK, Gonzalez MA, Ruggirello D, et al. Relative bioavailability of a new transdermal nitroglycerin delivery system.J Pharmaceut Sci 1986;75:688–691.

    Google Scholar 

  29. De Ponti F, Luca C, Pamparana F, et al. Bioavailability study of three transdermal nitroglycerin preparations in normal volunteers.Curr Ther Res 1989;46:111–120.

    Google Scholar 

  30. Wiegand A, Bonn R, Wagner F, et al. Haemodynamic effects of glyceryl trinitrate following repeated application of a transdermal delivery system with a phasic release profile.Eur J Clin Pharmacol 1991;41:115–118.

    Google Scholar 

  31. Noonan PK, Benet LZ. Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration.Clin Pharmacol Ther 1987;42:273–277.

    Google Scholar 

  32. Laufen H, Leitold M. The pattern of glyceryl nitrates after oral administration of glyceryl trinitrate.Arzneim Forsch/Drug Res 1988;38:103–105.

    Google Scholar 

  33. Laufen H, Leitold M. Glyceryl-1-nitrate pharmacokinetics in healthy volunteers.Br J Clin Pharmacol 1987;23:287–293.

    Google Scholar 

  34. Gumbleton M, Cashman JR, Benet LZ. 1,2- and 1,3-dinitrate metabolites of nitroglycerin: Spectroscopic characterization and initial administration to man.Int J Pharm 1991;71:175–186.

    Google Scholar 

  35. Leitold M, Laufen H, Yeates RA. Untersuchungen zur Pharmakologie and Pharmakokinetik von Glycerol-2-nitrat.Arzneim Forsch/Drug Res 1987;37:692–698.

    Google Scholar 

  36. Alpert JS. Nitrate therapy in the elderly.Am J Cardiol 1990;65:23J-27J.

    Google Scholar 

  37. Kelly JG, O'Malley K. Nitrates in the elderly. Pharmacological considerations.Drugs and Aging 1992;2:14–19.

    Google Scholar 

  38. Curry SH, Kwon H-R. Influence of posture on plasma nitroglycerin.Br J Clin Pharmacol 1985;19:403–404.

    Google Scholar 

  39. Heidemann R, Beckenbauer C, Woodcock BG. Effect of posture on glyceryl trinitrate plasma concentrations following transdermal application.Br J Clin Pharmacol 1987;23:246–247.

    Google Scholar 

  40. Lefebvre RA, Bogaert MG, Teirlynck O, et al. Influence of exercise on nitroglycerin plasma concentrations after transdermal application.Br J Clin Pharmacol 1990;30:292–296.

    Google Scholar 

  41. Barkve TF, Langseth-Manrique K, Bredesen JE, et al. Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature.Am Heart J 1986;112:537–541.

    Google Scholar 

  42. Weber S, de Lauture D, Rey E, et al. The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerin.Br J Clin Pharmacol 1987;23:103–105.

    Google Scholar 

  43. Gjesdal K, Klemsdal TO, Rykke EO, et al. Transdermal nitrate therapy: Bioavailability during exercise increases transiently after the daily change of patch.Br J Clin Pharmacol 1991;31:560–562.

    Google Scholar 

  44. Klemsdal TO, Gjesdal K, Bredesen J-E. Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.Eur J Clin Pharmacol 1992;43:625–628.

    Google Scholar 

  45. De Muynck C, Colardyn F, Remon JP. Influence of intravenous administration set composition on the absorption of isosorbide dinitrate.J Pharm Pharmacol 1991;43:601–604.

    Google Scholar 

  46. De Muynck C, Colardyn F, Remon JP. The absorption of isosorbide-5-mononitrate to intravenous delivery systems.J Pharm Pharmacol 1990;42:433–434.

    Google Scholar 

  47. Smith D, Aldrich W, Dey M, et al. A pharmacokinetic model for isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.Drug Metab Disp 1990;18:429–434.

    Google Scholar 

  48. Schneider W, Menke G, Heidemann R, et al. Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.Eur J Clin Pharmacol 1990;38:145–147.

    Google Scholar 

  49. Keller-Stanislawski B, Marschner J-P, Rietbrock N. Pharmakokinetik von niedrigdosiertem Isosorbiddinitrat und Metaboliten nach bukkaler und oraler Gabe.Arzneim Forsch/Drug Res 1992;42:17–20.

    Google Scholar 

  50. Menke G, Schnellhammer R, Rietbrock N. Konzentrations-Zeit-Profil von Isosorbiddinitrat und seinen Metaboliten im Plasma nach perkutaner Resorption aus einem transdermalen therapeutischen System.Arzneim Forsch/Drug Res 1987;37:1301–1303.

    Google Scholar 

  51. Laufen H, Leitold M. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.Arzneim Forsch/Drug Res 1992;42:931–935.

    Google Scholar 

  52. Nakatsu K, Brien JF, Savard G, et al. Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.Biopharm Drug Disp 1992;13:357–367.

    Google Scholar 

  53. Lemmer B, Scheidel B, Blume H, et al. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.Eur J Clin Pharmacol 1991;40:71–75.

    Google Scholar 

  54. Scheidel B, Lemmer B. Chronopharmacology of oral nitrates in healthy subjects.Chronobiol Int 1991;8:409–419.

    Google Scholar 

  55. Bogaert MG, Lefebvre RA, Rosseel MT, et al. Influence of exercise on plasma concentrations of isosorbide dinitrate.Eur J Clin Pharmacol 1988;35:213–215.

    Google Scholar 

  56. Thomson AH, Miller SHK, Green ST, et al. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.Eur J Clin Pharmacol 1988;34:47–50.

    Google Scholar 

  57. Bogaert MG, Rosseel MT, Boelaert J, et al. Fate of isosorbide dinitrate and mononitrates in patients with renal failure.Eur J Clin Pharmacol 1981;21:73–76.

    Google Scholar 

  58. Bauer H, Laufen H, Franz HE. Isosorbide dinitrate in plasma and dialysate during haemodialysis.Eur J Clin Pharmacol 1986;30:187–190.

    Google Scholar 

  59. Evers J, Bonn R, Boertz A, et al. Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. Eur J Clin Pharmacol 1987;32:503–505.

    Google Scholar 

  60. Meissner A, Petersenn S, Heidemann HT, et al. Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.Klin Wochenschr 1991;69:213–219.

    Google Scholar 

  61. Chasseaud LF, Doyle E, Taylor T. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.Biopharm Drug Disp 1981;2:273–281.

    Google Scholar 

  62. Bogaert MG, Rosseel MT, Bruyneel K. Single administration of atenolol does not influence the kinetics of orally given isosorbide dinitrate.Int J Clin Pharmacol Res 1983;3:491–493.

    Google Scholar 

  63. Ochs HR, Neugebauer G, Greenblatt DJ, et al. Influence of beta-blocker coadministration on the kinetics of isosorbide mononitrate and dinitrate.Klin Wochenschr 1986;64:1213–1216.

    Google Scholar 

  64. Lefebvre RA, De Wilde G, Rosseel MT, et al. Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.Eur J Clin Pharmacol 1992;42:549–552.

    Google Scholar 

  65. Bogaert MG, Herman AH, De Schaepdryver AF. Effects of nitroglycerin (trinitrin) on vascular smooth muscle.Eur J Pharmacol 1970;12:215–223.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heymans Institute of Pharmacology, University of Gent Medical School, De Pintelaan 185, B-9000, Gent, Belgium

    Marc G. Bogaert

Authors
  1. Marc G. Bogaert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogaert, M.G. Clinical pharmacokinetics of nitrates. Cardiovasc Drug Ther 8, 693–699 (1994). https://doi.org/10.1007/BF00877116

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877116

Key Words

Search

Navigation